The Laetose™ technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, while also inhibiting tumor necrosis factor alpha (TNF-α), a cytokine associated with inflammatory chronic diseases.
The patented formulation is a novel combination of one or more sugars and myo-inositol, with potential to inhibit the inflammatory and metabolic response of sugar alone. This marks the first Laetose™ patent issued in the
The patented Laetose™ composition consists of an effective amount of sugar and myo-inositol, with potential applications in therapeutic administration to reduce or limit inflammatory or metabolic diseases (e.g., diabetes). The composition mitigates a TNF-α response to the sugar.
Potential Applications and Market Impact:
- US Inflammatory Disease Treatment Market: Estimated at
$35B (source:Precedence Research 2022) - US Diabetes Treatment Market: Currently at
$30B and projected to grow to$61B by 2028 (source: GlobeNewswire 2022) - US Refined Sugar Production Market: Valued at
$12B and expected to grow to$26B by 2028 (source: Knowledge Sourcing Intelligence)
Impact Biomedical CEO
About
About
Safe Harbor Disclosure: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations and Media Contact:
Contact:
IR@dssworld.com
+1 (585) 565-2422
Source:
2024 GlobeNewswire, Inc., source